[go: up one dir, main page]

PE20060186A1 - SELECTED CGRP ANTAGONISTS, PROCEDURES FOR THEIR PREPARATION AS WELL AS THEIR USE AS A MEDICINE - Google Patents

SELECTED CGRP ANTAGONISTS, PROCEDURES FOR THEIR PREPARATION AS WELL AS THEIR USE AS A MEDICINE

Info

Publication number
PE20060186A1
PE20060186A1 PE2005000434A PE2005000434A PE20060186A1 PE 20060186 A1 PE20060186 A1 PE 20060186A1 PE 2005000434 A PE2005000434 A PE 2005000434A PE 2005000434 A PE2005000434 A PE 2005000434A PE 20060186 A1 PE20060186 A1 PE 20060186A1
Authority
PE
Peru
Prior art keywords
piperidin
oxo
methyl
benzodiazepin
piperazin
Prior art date
Application number
PE2005000434A
Other languages
Spanish (es)
Inventor
Stephan Georg Muller
Klaus Rudolf
Dirk Stenkamp
Fabio Paleari
Kirsten Arndt
Henri Doods
Gerhard Schaenzle
Marco Santagostino
Phillip Lusteberger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20060186A1 publication Critical patent/PE20060186A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES O, S; X ES O, S; Q ES UN HETEROCICLO CONSISTENTE EN 2 O3 ANILLOS CONDENSADOS, EN CADA CASO DE 4-8 MIEMBROS, SATURADOS, PARCIAL O TOTALMENTE INSATURADOS INDEPENDIENTEMENTE UNO DE OTRO, DONDE EL HETEROCICLO PRESENTA 1-5 HETEROATOMOS, SELECCIONADOS ENTRE O, N, S; R1 ES HETEROCICLO AZA, DIAZA, OXAZA, S,S-DIOXIDO-TIADIAZA, ENTRE OTROS; R2 ES H, FENILMETILO, ALQUILO C2-C7 SUSTIUTIDO, ENTRE OTROS; R3 ES H, ALQUILO C1-C3 SUSTITUIDO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ESTER (R)-1-(7-METIL-1H-INDAZOL-5-ILMETIL)-2-[4-(4-METIL-PIPERAZIN-1-IL)-PIPERIDIN-1-IL]-2-OXO-ETILICO DE ACIDO 4-(2-OXO-1,2,4,5-TETRAHIDRO-1,3-BENZODIAZEPIN-3-IL)PIPERIDIN-1-CARBOXILICO; ESTER (R)-1-(4-AMINO-3-METIL-5-NITRO-BENCIL)-2-[4-(4-METIL-PIPERAZIN-1-IL)-PIPERIDIN-1-IL]-2-OXO-ETILICO DE ACIDO 4-(2-OXO-1,2,4,5-TETRAHIDRO-1,3-BENZODIAZEPIN-3-IL)PIPERIDIN-1-CARBOXILICO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON ANTAGONISTAS DE CGRP UTILES EN EL TRATAMIENTO AGUDO O PROFILACTICO DE CEFALEAS, ENFERMEDADES CARDIOVASCULARES, ARTRITIS, ENTRE OTROSREFERS TO A COMPOUND OF FORMULA I, WHERE A IS O, S; X IS O, S; Q IS A HETEROCYCLE CONSISTENT OF 2 OR 3 CONDENSED RINGS, IN EACH CASE OF 4-8 MEMBERS, SATURATED, PARTIALLY OR TOTALLY INSATURATED, INDEPENDENTLY ONE OF THE OTHER, WHERE THE HETEROCYCLE PRESENTS 1-5 HETEROATOMS, SELECTED AMONG O, N, S; R1 IS HETEROCICLO AZA, DIAZA, OXAZA, S, S-DIOXIDO-TIADIAZA, AMONG OTHERS; R2 IS H, PHENYLMETHYL, SUBSTITUTED C2-C7 ALKYL, AMONG OTHERS; R3 IS H, C1-C3 ALKYL SUBSTITUTED, AMONG OTHERS. PREFERRED COMPOUNDS ARE: ESTER (R) -1- (7-METHYL-1H-INDAZOL-5-ILMETYL) -2- [4- (4-METHYL-PIPERAZIN-1-IL) -PIPERIDIN-1-IL] -2 -OXO-ETHYL OF 4- (2-OXO-1,2,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-3-IL) PIPERIDIN-1-CARBOXYL ACID; ESTER (R) -1- (4-AMINO-3-METHYL-5-NITRO-BENZYL) -2- [4- (4-METHYL-PIPERAZIN-1-IL) -PIPERIDIN-1-IL] -2-OXO - 4- (2-OXO-1,2,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-3-IL) PIPERIDIN-1-CARBOXYL ACID ETHYL; AMONG OTHERS. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. SUCH COMPOUNDS ARE USEFUL ANTAGONISTS OF CGRP IN THE ACUTE OR PROPHYLACTIC TREATMENT OF HEADACHES, CARDIOVASCULAR DISEASES, ARTHRITIS, AMONG OTHERS

PE2005000434A 2004-04-22 2005-04-20 SELECTED CGRP ANTAGONISTS, PROCEDURES FOR THEIR PREPARATION AS WELL AS THEIR USE AS A MEDICINE PE20060186A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004019492A DE102004019492A1 (en) 2004-04-22 2004-04-22 Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
PE20060186A1 true PE20060186A1 (en) 2006-04-18

Family

ID=35140095

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000434A PE20060186A1 (en) 2004-04-22 2005-04-20 SELECTED CGRP ANTAGONISTS, PROCEDURES FOR THEIR PREPARATION AS WELL AS THEIR USE AS A MEDICINE

Country Status (9)

Country Link
EP (1) EP1740577A2 (en)
JP (1) JP2007533689A (en)
AR (1) AR049422A1 (en)
CA (1) CA2565219A1 (en)
DE (1) DE102004019492A1 (en)
PE (1) PE20060186A1 (en)
TW (1) TW200606151A (en)
UY (1) UY28859A1 (en)
WO (1) WO2005103037A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (en) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
AR046787A1 (en) 2003-12-05 2005-12-21 Bristol Myers Squibb Co HETEROCICLIC ANTIMIGRAN AGENTS
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (en) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) * 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
DE102004063752A1 (en) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of selected CGRP antagonists to combat menopausal hot flashes
DE102004063753A1 (en) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of selected CGRP antagonists in combination with other migraine medicines for the treatment of migraine
EP1770091A1 (en) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-antagonists, process for their preparation as well as their use as medicaments
DE102005038831A1 (en) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New N-acylalkoxycarbonyl-piperidine derivatives, useful as CGRP antagonists, for treating e.g. headaches, cardiovascular disease, skin disorders, morphine tolerance, and inflammatory diseases such as osteoarthritis and allergic rhinitis
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
DE102005050892A1 (en) * 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
CA2654048A1 (en) * 2006-06-08 2007-12-13 Boehringer Ingelheim International Gmbh Treatment of gastrointestinal disorders with cgrp antagonists
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CN101573340A (en) 2006-11-01 2009-11-04 百时美施贵宝公司 Modulators of glucocorticoid receptor AP-1 and/or NF-kB activity and uses thereof
KR20100091972A (en) 2007-10-18 2010-08-19 베링거 인겔하임 인터내셔날 게엠베하 Cgrp antagonists
EP2065381A1 (en) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP antagonists
EP2225223B1 (en) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organic compounds
AR084706A1 (en) * 2010-07-16 2013-06-05 Piramal Life Sciences Ltd SUBSTITUTED DERIVATIVES OF IMIDAZOQUINOLINAS AS QUINASE INHIBITORS AND PROCESS FOR PREPARATION
JP2016532721A (en) 2013-10-07 2016-10-20 バイエル ファーマ アクチエンゲゼルシャフト Cyclic thienouracil carboxamide and uses thereof
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
JP6695441B2 (en) 2016-03-03 2020-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4-Cyano-benzylcarbamimidoylcarbamate derivatives and their use as AOC3 inhibitors
JP6647417B2 (en) 2016-03-03 2020-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyridinylmethylcarbamimidylcarbamate derivatives and their use as AOC3 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE266673T1 (en) * 1996-09-10 2004-05-15 Boehringer Ingelheim Pharma MODIFIED AMINO ACIDS, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
CA2345357A1 (en) * 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
DE19937304C2 (en) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Use of CGRP antagonists to combat menopausal hot flashes
DE10300973A1 (en) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New carboxylic acids and their esters, medicaments containing these compounds and processes for their preparation
DE102004015723A1 (en) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine

Also Published As

Publication number Publication date
JP2007533689A (en) 2007-11-22
WO2005103037A2 (en) 2005-11-03
TW200606151A (en) 2006-02-16
DE102004019492A1 (en) 2005-11-10
CA2565219A1 (en) 2005-11-03
WO2005103037A3 (en) 2006-01-12
AR049422A1 (en) 2006-08-02
EP1740577A2 (en) 2007-01-10
UY28859A1 (en) 2005-11-30

Similar Documents

Publication Publication Date Title
PE20060186A1 (en) SELECTED CGRP ANTAGONISTS, PROCEDURES FOR THEIR PREPARATION AS WELL AS THEIR USE AS A MEDICINE
PE20080538A1 (en) FUSED HETEROCYCLIC DERIVATIVE AND ITS USE
PE20221628A1 (en) RIP1 INHIBITOR COMPOUNDS AND METHODS FOR MAKING AND USING THEM
PE20080404A1 (en) BENZYL-AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS
PE20070218A1 (en) AMINO-HYDANTOIN CYCLOALKYL COMPOUNDS AND USE OF THESE FOR THE MODULATION OF ß-SECRETASE
PE20060215A1 (en) 4-PHENYLAMINE-QUINAZOLIN-6-IL-AMIDES
BRPI0406762A (en) N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidincarb oxamide derivatives and related compounds as cgrp antagonists for treatment of headaches
PE20090620A1 (en) DERIVATIVES OF 1,2,4,5-TETRAHIDRO-3H-BENZAZEPINEAS, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PE20091884A1 (en) SELECTED CGRP ANTAGONISTS, PROCEDURE FOR THEIR PREPARATION, AS WELL AS THEIR USE AS A MEDICINE
PE20061357A1 (en) COMPOUNDS DERIVED FROM AMINOSULFONIL AS INHIBITORS OF 11-ß-HSD-1
PE20090601A1 (en) PYRIDIN-IL-OXY-PYRIDINES DERIVATIVES AS ALK5 INHIBITORS
NO20073729L (en) Heterocyclic Compounds as CCR2B Antagonists
PE20090813A1 (en) 11B-HYDROXIESTEROID-DEHYDROGENASE INHIBITORS
PE20081845A1 (en) NEW AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS
PE20020381A1 (en) PIRROLO [2,3-d] PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS
PE20070217A1 (en) ISOQUINOLONE DERIVATIVES SUBSTITUTED WITH PIPERIDINYL
PE20061436A1 (en) DERIVATIVES OF AMIDE SUBSTITUTED AS PROTEIN KINASE INHIBITORS
PE20090958A1 (en) MODULATING HETEROCYCLIC COMPOUNDS OF MYOSIN
PE20040780A1 (en) HETEROCICLIC COMPOUNDS AS ANTAGONIST OF CGRP AND PROCEDURE FOR THEIR PREPARATION
PE20141681A1 (en) BTK INHIBITORS
PE20081164A1 (en) NEW COMPOUNDS 521
DE602005008558D1 (en) CONDENSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF METABOTROPIC REINFORCEMENTS
PE20121440A1 (en) OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
UA98966C2 (en) BENZAZEPIN DERIVATIVES SUITABLE FOR USE AS VASOPRESIN ANTAGONISTS
PE20120632A1 (en) BACE INHIBITORS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal